How we generate value

Building an exciting pipeline

Highlights

Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia

The Phase 2 double-blind placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD. Rejuvenate Biomed anticipates commencing patient enrollment first half 2025

LEARN MORE

Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools

Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools

LEARN MORE

Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia.

LEARN MORE

Committed to a sustainable future

After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.

LEARN MORE

Clinical-stage biotech dedicated to the discovery and development of therapeutics to delay the onset of multiple age-related diseases

How we generate value

Building an exciting pipeline

Highlights

Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia

Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools

Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

Committed to a sustainable future

Acknowledgements and investors

Clinical-stage biotech dedicated to the discovery and development of therapeutics
to delay the onset of multiple age-related diseases